Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Neoplasms malignant site unspecified NEC
ADR ID BADD_A03009
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.16      Miscellaneous and site unspecified neoplasms malignant and unspecified
16.16.01      Neoplasms malignant site unspecified NEC
Description Not Available
MedDRA Code 10029105
MeSH ID Not Available
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE)
Synonym
Not Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D02184Tetraferric tricitrate decahydrate0.001239%
BADD_D02192Thalidomide0.000241%
BADD_D02203Thiotepa--
BADD_D02208Thyrotropin alfa--
BADD_D02214Ticagrelor--
BADD_D02230Tizanidine--
BADD_D02231Tizanidine hydrochloride--
BADD_D02234Tocilizumab--
BADD_D02236Tofacitinib0.025413%
BADD_D02237Tofacitinib citrate--
BADD_D02241Tolcapone--
BADD_D02244Tolterodine0.000226%
BADD_D02246Tolvaptan0.000523%
BADD_D02248Topotecan0.000672%
BADD_D02249Topotecan hydrochloride--
BADD_D02252Tositumomab--
BADD_D02257Trametinib0.007510%
BADD_D02258Trametinib dimethyl sulfoxide--
BADD_D02265Travoprost0.000367%
BADD_D02270Tretinoin--
BADD_D02312Ulipristal--
BADD_D02322Ustekinumab--
BADD_D02325Valdecoxib--
BADD_D02331Valsartan0.000979%
BADD_D02334Vandetanib0.000224%
BADD_D02337Varenicline0.001557%
BADD_D02342Vedolizumab--
BADD_D02344Vemurafenib0.008260%
BADD_D02345Venetoclax0.001142%
BADD_D02346Venlafaxine0.000209%
The 11th Page    First    Pre   11 12 13 14    Next   Last    Total 14 Pages